NL300181I1 - N-(pyrroloÄ2,3-dÜpyrimidine-3-ylacyl)-glutaminezuurderivaten. - Google Patents

N-(pyrroloÄ2,3-dÜpyrimidine-3-ylacyl)-glutaminezuurderivaten.

Info

Publication number
NL300181I1
NL300181I1 NL300181C NL300181C NL300181I1 NL 300181 I1 NL300181 I1 NL 300181I1 NL 300181 C NL300181 C NL 300181C NL 300181 C NL300181 C NL 300181C NL 300181 I1 NL300181 I1 NL 300181I1
Authority
NL
Netherlands
Prior art keywords
ylacyl
dpyrimidine
pyrrolo
glutamic acid
acid derivatives
Prior art date
Application number
NL300181C
Other languages
English (en)
Other versions
NL300181I2 (nl
Original Assignee
Univ Princeton
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27503964&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NL300181(I1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US07/528,805 external-priority patent/US4996206A/en
Application filed by Univ Princeton, Lilly Co Eli filed Critical Univ Princeton
Publication of NL300181I1 publication Critical patent/NL300181I1/nl
Publication of NL300181I2 publication Critical patent/NL300181I2/nl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/582—Recycling of unreacted starting or intermediate materials

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
NL300181C 1989-12-11 2005-03-16 N-(pyrroloÖÄ2,3-dÖÜpyrimidine-3-ylacyl)-glutaminezuurderivaten. NL300181I2 (nl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US44874289A 1989-12-11 1989-12-11
US47965590A 1990-02-08 1990-02-08
US07/528,805 US4996206A (en) 1989-12-11 1990-05-24 N-(pyrrolo[2,3-d]pyrimidin-3-ylacyl)-glutamic acid derivatives
US07/528,155 US5028608A (en) 1989-12-11 1990-05-24 N-(6-Amino-(pyrrolo(2,3-d)pyrimidin-3-ylacyl) )-glutamic acid derivatives

Publications (2)

Publication Number Publication Date
NL300181I1 true NL300181I1 (nl) 2005-05-02
NL300181I2 NL300181I2 (nl) 2005-06-01

Family

ID=27503964

Family Applications (1)

Application Number Title Priority Date Filing Date
NL300181C NL300181I2 (nl) 1989-12-11 2005-03-16 N-(pyrroloÖÄ2,3-dÖÜpyrimidine-3-ylacyl)-glutaminezuurderivaten.

Country Status (22)

Country Link
EP (1) EP0432677B1 (nl)
JP (1) JP3016876B2 (nl)
CN (1) CN1030608C (nl)
AR (1) AR245129A1 (nl)
AT (1) ATE135007T1 (nl)
AU (1) AU640182B2 (nl)
CA (1) CA2031890C (nl)
CY (1) CY2076B1 (nl)
DE (2) DE122005000012I2 (nl)
DK (1) DK0432677T3 (nl)
ES (1) ES2084639T4 (nl)
GR (1) GR3019784T3 (nl)
HK (1) HK1000920A1 (nl)
HU (1) HU218483B (nl)
IE (1) IE904445A1 (nl)
IL (1) IL96531A (nl)
LU (1) LU91147I2 (nl)
NL (1) NL300181I2 (nl)
NZ (1) NZ236385A (nl)
PT (1) PT96140B (nl)
RU (1) RU2057131C9 (nl)
SG (1) SG48098A1 (nl)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5254687A (en) 1991-12-04 1993-10-19 The Trustees Of Princeton University Process for the preparation of pyrrolo[2,3-d]pyrimidines
US5235053A (en) * 1992-06-22 1993-08-10 Eli Lilly And Company Process for the synthesis of 4-hydroxy-5-halopyrrold[2,3-d]pyrimidine intermediates
AU2003217676B2 (en) 2002-02-22 2009-06-11 Takeda Pharmaceutical Company Limited Active agent delivery systems and methods for protecting and administering active agents
CN100344615C (zh) * 2004-11-25 2007-10-24 重庆医药工业研究院有限责任公司 制备N－(吡咯并[2,3－d]嘧啶－5－基)酰基谷氨酸衍生物的方法及中间体
AU2006207321B2 (en) 2005-01-21 2012-09-06 Astex Therapeutics Limited Pharmaceutical compounds
US8629152B2 (en) 2006-08-14 2014-01-14 Sicor, Inc. Processes for the preparation of lyophilized pharmaceutically acceptable salts of pemetrexed diacid
EP2322526A1 (en) 2006-08-14 2011-05-18 Sicor, Inc. Crystalline form of pemetrexed diacid and process for the preparation thereof
EP1934226A2 (en) 2006-08-14 2008-06-25 Sicor, Inc. Highly pure pemetrexed diacid and processes for the preparation thereof
TWI374886B (en) 2006-08-14 2012-10-21 Sicor Inc Processes for preparing intermediates of pemetrexed
WO2008044045A1 (en) 2006-10-12 2008-04-17 Astex Therapeutics Limited Pharmaceutical combinations
JP5528806B2 (ja) 2006-10-12 2014-06-25 アステックス、セラピューティックス、リミテッド 複合薬剤
CN101417998B (zh) 2007-10-24 2012-10-24 重庆医药工业研究院有限责任公司 一种培美曲塞盐的纯化方法
AU2015210337B2 (en) * 2008-06-06 2017-02-02 Boehringer Ingelheim International Gmbh Pharmaceutical combination
RS57035B1 (sr) * 2008-06-06 2018-05-31 Boehringer Ingelheim Int Farmaceutska kombinacija
CN101684121B (zh) * 2008-09-22 2013-04-03 重庆医药工业研究院有限责任公司 培美曲塞二酸的新晶型及其制备方法
EP2504341A1 (en) 2009-11-24 2012-10-03 Azad Pharmaceutical Ingredients AG A new crystalline form of pemetrexed disodium
DK2854768T3 (en) 2012-05-30 2017-06-12 Fresenius Kabi Oncology Ltd PHARMACEUTICAL COMPOSITIONS OF PEMETREXED
ITRM20120398A1 (it) 2012-08-08 2014-02-09 Berlin Chemie Ag Procedimento di sintesi pemetrexed e suo sale di lisina.
WO2014167585A1 (en) 2013-04-12 2014-10-16 Actavis Group Ptc Ehf. Pemetrexed formulation
EP2997031A1 (en) 2013-05-17 2016-03-23 Instytut Farmaceutyczny Process for the preparation of high purity amorphous pemetrexed disodium and crystalline forms of n-[4-[2-(2-amino-4,7-dihydro-4-oxo-3h-pyrrolo[2,3- d]pyrimidin-5-yl)ethyl]benzoyl]-l-glutamic acid
WO2014198338A1 (en) 2013-06-14 2014-12-18 Synthon B.V. Stable pemetrexed arginine salt and compositions comprising it
EP3021849B1 (en) 2013-07-16 2019-10-09 Dr. Reddy's Laboratories Ltd. Novel crystalline forms of pemetrexed tromethamine salts
NZ630292A (en) 2013-11-25 2015-02-27 Shilpa Medicare Ltd Process for crystalline pemetrexed dipotassium salt
RS60183B1 (sr) 2014-10-16 2020-06-30 Synthon Bv Tečna farmaceutska kompozicija koja sadrži pemetreksed
CN104672241B (zh) * 2015-01-29 2018-04-24 王磊 吡咯并[2,3-d]嘧啶类化合物及其用途
FR3037956B1 (fr) * 2015-06-23 2017-08-04 Servier Lab Nouveaux derives d'acide amine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
CA3017411A1 (en) 2016-03-15 2017-09-21 Oryzon Genomics, S.A. Combinations of lsd1 inhibitors for use in the treatment of solid tumors
EP3675864A4 (en) * 2017-08-31 2022-02-16 Duquesne University of The Holy Spirit FIRST REPRESENTATIVES OF SHMT2 AND MTHFD2 INHIBITORS AS ANTITUMORS
CN110305135B (zh) * 2018-03-20 2022-02-22 鲁南制药集团股份有限公司 一种培美曲塞二钠中间体及其制备方法
CN110305137A (zh) * 2018-03-20 2019-10-08 鲁南制药集团股份有限公司 一种培美曲塞二钠中间体及其制备方法
CN110305134B (zh) * 2018-03-20 2022-02-22 鲁南制药集团股份有限公司 一种培美曲塞二钠中间体及其制备方法
CN110305136A (zh) * 2018-03-20 2019-10-08 鲁南制药集团股份有限公司 一种培美曲塞二钠中间体及其制备方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4818819A (en) * 1986-10-20 1989-04-04 The Trustees Of Princeton University Process for the preparation of fused pyridine compounds
NO169490C (no) * 1988-03-24 1992-07-01 Takeda Chemical Industries Ltd Analogifremgangsmaate for fremstilling av terapeutisk aktive pyrrolopyrimidinderivater
DK172753B1 (da) * 1988-05-25 1999-06-28 Lilly Co Eli N-(5,6,7,8-tetrahydropyrido[2,3--d]pyrimidin-6-yl-alkanoyl)-glutaminsyrederivater, deres anvendelse, farmaceutiske præparat
US4883799A (en) * 1988-06-29 1989-11-28 The Trustees Of Princeton University N-(4-(1-hydroxy-3-(5,6,7,8-tetrahydropyrido(2,3,-d)-pyrimidin-6-yl)prop-2-yl)benzoyl)glutamic acid derivatives

Also Published As

Publication number Publication date
CN1030608C (zh) 1996-01-03
HK1000920A1 (en) 1998-05-08
IL96531A0 (en) 1991-09-16
SG48098A1 (en) 1998-04-17
DE122005000012I2 (de) 2006-02-09
ES2084639T3 (es) 1996-05-16
RU2057131C1 (ru) 1996-03-27
IL96531A (en) 1995-08-31
CY2076B1 (en) 1998-09-11
LU91147I2 (fr) 2005-05-17
CA2031890C (en) 2000-07-25
DE69025723T2 (de) 1996-10-31
AU6779190A (en) 1991-06-13
ATE135007T1 (de) 1996-03-15
RU2057131C9 (ru) 2006-04-10
CA2031890A1 (en) 1991-06-12
DK0432677T3 (da) 1996-04-09
AR245129A1 (es) 1993-12-30
DE69025723D1 (de) 1996-04-11
JPH083166A (ja) 1996-01-09
CN1055182A (zh) 1991-10-09
DE122005000012I1 (de) 2005-06-23
HU218483B (hu) 2000-09-28
AU640182B2 (en) 1993-08-19
PT96140A (pt) 1991-09-30
EP0432677A1 (en) 1991-06-19
ES2084639T4 (es) 2013-06-11
EP0432677B1 (en) 1996-03-06
NZ236385A (en) 1992-05-26
GR3019784T3 (en) 1996-07-31
HU908147D0 (en) 1991-06-28
PT96140B (pt) 1997-06-30
IE904445A1 (en) 1991-06-19
HUT58335A (en) 1992-02-28
JP3016876B2 (ja) 2000-03-06
NL300181I2 (nl) 2005-06-01

Similar Documents

Publication Publication Date Title
NL300181I1 (nl) N-(pyrroloÄ2,3-dÜpyrimidine-3-ylacyl)-glutaminezuurderivaten.
DE68915207D1 (de) Aminosäure-Derivate.
NO901399L (no) Aminosyrederivater.
DE69016335D1 (de) Pantothensäure Derivate.
LV5742B4 (lv) 3,5-divalizvietoti pirokatehina atvasinajumi
DE59008394D1 (de) Aminosäureamid-Derivate.
NO901033L (no) Aminosyrederivater.
NO903832L (no) Aminosyrederivater.
ATE99668T1 (de) Polyaminderivate.
DE3763411D1 (de) 1,2,3,6-tetrahydro-5-nitro-pyrimidin-derivate.
DE3787657D1 (de) Aminosäure-Derivate.
DE59005313D1 (de) 2-Methyl- und 2-Hydroxymethyl-serin-N,N-diessigsäure und ihre Derivate.
NO901533L (no) Aminosyrederivater.
FI881612A (fi) Nya pyrrolidin-2-(1,3-dikarbonyl) -derivat, foerfaranden foer deras framstaellning, dessa innehaollande aemnen saovael som deras anvaendning.
NO900025D0 (no) Pyrrolylfenyl-substituerte hydroksamsyrederivater.
NO883070D0 (no) 4-aminosubstituerte 1,2-dihydroksynaftalin-derivater.
DE3887281D1 (de) 1,2,3,4-Tetrahydro-5-nitro-pyrimidin-Derivate.
DK10190D0 (da) 1,1-dioxo-cephem-4-carbothiolsyrederivater
DE3765646D1 (de) 2,5,6,7-tetranor-4,8-inter-m-phenylen-pgi2-derivate.
DE69122555D1 (de) 2,4-Dihydroxyadipinsäurederivate
DE3888097D1 (de) 1,2,3,4-Tetrahydro-5-nitro-pyrimidin-Derivate.
FI880320A (fi) Foerfarande foer framstaellning av n,n-(dibensohexatrienylen) urinaemnen.
DE69018816D1 (de) Aminosäurederivate.
DE59002430D1 (de) Cyclopropanoylaminosäureamid-Derivate.
NO901519L (no) Aminosyrederivater.